Market closed
KalVista Pharmaceuticals/$KALV
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About KalVista Pharmaceuticals
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Ticker
$KALV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
150
Website
KALV Metrics
BasicAdvanced
$496M
-
-$3.66
0.83
-
Price and volume
Market cap
$496M
Beta
0.83
52-week high
$15.50
52-week low
$7.30
Average daily volume
316K
Financial strength
Current ratio
6.87
Quick ratio
6.87
Long term debt to equity
3.489
Total debt to equity
4.636
Management effectiveness
Return on assets (TTM)
-71.62%
Return on equity (TTM)
-125.90%
Valuation
Price to book
3.24
Price to tangible book (TTM)
3.24
Price to free cash flow (TTM)
-3.486
Growth
Earnings per share change (TTM)
19.41%
3-year earnings per share growth (CAGR)
10.42%
What the Analysts think about KALV
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for KalVista Pharmaceuticals stock.
KALV Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KALV Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KALV News
AllArticlesVideos
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025
Seeking Alpha·2 months ago
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for KalVista Pharmaceuticals stock?
KalVista Pharmaceuticals (KALV) has a market cap of $496M as of February 25, 2025.
What is the P/E ratio for KalVista Pharmaceuticals stock?
The price to earnings (P/E) ratio for KalVista Pharmaceuticals (KALV) stock is 0 as of February 25, 2025.
Does KalVista Pharmaceuticals stock pay dividends?
No, KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next KalVista Pharmaceuticals dividend payment date?
KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders.
What is the beta indicator for KalVista Pharmaceuticals?
KalVista Pharmaceuticals (KALV) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.